179 related articles for article (PubMed ID: 23377373)
1. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Tsimberidou AM; Ye Y; Wheler J; Naing A; Hong D; Nwosu U; Hess KR; Wolff RA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):955-63. PubMed ID: 23377373
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers.
Sen S; Kato S; Agarwal R; Piha-Paul S; Hess K; Karp D; Janku F; Fu S; Naing A; Pant S; Falchook G; Tang C; Wu X; Ye Y; Tsimberidou A; Subbiah V; Kurzrock R; Byers L; Westin S; Lim J; Bean S; Bass A; Nguyen L; Meric-Bernstam F; Hong D
Br J Cancer; 2018 May; 118(11):1419-1424. PubMed ID: 29695765
[TBL] [Abstract][Full Text] [Related]
3. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Ko AH; Truong TG; Kantoff E; Jones KA; Dito E; Ong A; Tempero MA
Cancer Chemother Pharmacol; 2012 Dec; 70(6):875-81. PubMed ID: 23053263
[TBL] [Abstract][Full Text] [Related]
5. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study.
Feliu J; Jorge Fernández M; Macarulla T; Massuti B; Albero A; González González JF; Quintero-Aldana G; Delgado-Mingorance JI; Fernández Montes A; García Piernavieja C; Valladares-Ayerbes M; López Muñoz AM; Mondéjar Solís R; Vicente P; Casado Gonzalez E; González Cebrián I; López-Vivanco G
Cancer Chemother Pharmacol; 2021 Apr; 87(4):543-553. PubMed ID: 33452559
[TBL] [Abstract][Full Text] [Related]
8. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer.
Shabason JE; Chen J; Apisarnthanarax S; Damjanov N; Giantonio B; Loaiza-Bonilla A; O'Dwyer PJ; O'Hara M; Reiss KA; Teitelbaum U; Wissel P; Drebin JA; Vollmer C; Kochman M; Mick R; Vergara N; Jhala N; Doucette A; Lukens JN; Plastaras JP; Metz JM; Ben-Josef E
Cancer Chemother Pharmacol; 2018 Mar; 81(3):609-614. PubMed ID: 29362902
[TBL] [Abstract][Full Text] [Related]
10. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
Trials; 2015 Dec; 16():575. PubMed ID: 26673577
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
Zhang DS; Wang DS; Wang ZQ; Wang FH; Luo HY; Qiu MZ; Wang F; Li YH; Xu RH
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1065-72. PubMed ID: 23483298
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver.
Tsimberidou AM; Fu S; Ng C; Lim JA; Wen S; Hong D; Wheler J; Bedikian AY; Eng C; Wallace M; Camacho LH; Kurzrock R
Cancer; 2010 Sep; 116(17):4086-94. PubMed ID: 20564148
[TBL] [Abstract][Full Text] [Related]
14.
Korn RL; Von Hoff DD; Borad MJ; Renschler MF; McGovern D; Curtis Bay R; Ramanathan RK
Cancer Imaging; 2017 Aug; 17(1):23. PubMed ID: 28774338
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
16. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
[TBL] [Abstract][Full Text] [Related]
17. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Lobo C; Lopes G; Baez O; Castrellon A; Ferrell A; Higgins C; Hurley E; Hurley J; Reis I; Richman S; Seo P; Silva O; Slingerland J; Tukia K; Welsh C; Glück S
Breast Cancer Res Treat; 2010 Sep; 123(2):427-35. PubMed ID: 20585851
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Dotan E; Cardin DB; Lenz HJ; Messersmith W; O'Neil B; Cohen SJ; Denlinger CS; Shahda S; Astsaturov I; Kapoun AM; Brachmann RK; Uttamsingh S; Stagg RJ; Weekes C
Clin Cancer Res; 2020 Oct; 26(20):5348-5357. PubMed ID: 32694153
[TBL] [Abstract][Full Text] [Related]
19. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.
Cohen SJ; O'Neil BH; Berlin J; Ames P; McKinley M; Horan J; Catalano PM; Davies A; Weekes CD; Leichman L
Cancer Chemother Pharmacol; 2016 Apr; 77(4):693-701. PubMed ID: 26886016
[TBL] [Abstract][Full Text] [Related]
20. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
O'Reilly EM; Roach J; Miller P; Yu KH; Tjan C; Rosano M; Krause S; Avery W; Wolf J; Flaherty K; Nix D; Ryan DP
Oncologist; 2017 Dec; 22(12):1429-e139. PubMed ID: 29158367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
